BioSpace News Archive

As per Precedence Research, the immunotherapy drugs market size is expected to hit US$ 324.83 billion by 2030 from valued at US$ 176.94 billion in 2021, growing at a CAGR of 7.9%.

As per Precedence Research, the In Vitro Diagnostics (IVD) market size estimated at US$ 85.23 billion by 2027 and growing at a CAGR of 5% during the forecast period 2021 to 2027.

Building on the strong 2021 year in which Aerolase revenues grew 120%, Aerolase is pleased to announce a new major growth initiative to further enhance the company’s offering for dermatologists not concentrated on aesthetics.

Histogen Inc. announced the closing of its previously announced private placement for the issuance and sale of 2,500 shares of Series A redeemable convertible preferred stock and 2,500 shares of Series B redeemable convertible preferred stock.

SQI Diagnostics Inc. announced today that Company CEO Andrew Morris has been invited to present at the 2022 Virtual Growth Conference.

Oxurion NV, a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, published its annual report for the financial year 2021.

Exicure, Inc. today reported full year financial results for the quarter and year ended December 31, 2021 and provided an update on its business strategy and corporate progress.

Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, announced that, on March 21, 2022, it granted an option to purchase 1,704,328 shares of Jasper’s voting common stock to Ronald Martell, Jasper’s newly appointed President and Chief Executive Officer.

Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, today announced topline interim results from its ongoing Phase 1/2 clinical trial of IVX-411, a VLP vaccine candidate displaying the SARS-CoV-2 receptor-binding domain (RBD).

Noema Pharma, a Swiss-based clinical-stage company targeting orphan and large-market central nervous system diseases, announces it will participate in the Stifel 2022 CNS Days conference, being held virtually from March 28 to 29, 2022.